Clinical management of allergic rhinitis - The allergy society of South Africa consensus update

South African Medical Journal

Volumn 96, Issue 12 II, 2006, Pages 1269-1272

  Potter, P C ^a   Carte, G ^b   Davis, G ^b   Desmarais, P ^b   Friedman, R ^b   Gill, M ^b   Gravet, C ^b   Green, R ^b   Groenewald, M ^b   Hockman, M ^b   Jeena, P ^b   Jooma, O ^b   Joyce, G ^b   Manjra, A ^b   Ossip, M ^b   Seedat, R ^b   Steer, J ^b   Vidjak, D ^b   Wolff, L ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; ANTIHISTAMINIC AGENT; BECLOMETASONE; BETAMETHASONE; CELESTAMINE; CETIRIZINE; CORTICOSTEROID; CORTISONE; DESLORATADINE; FEXOFENADINE; GENERIC DRUG; HERBACEOUS AGENT; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; NON PRESCRIPTION DRUG; PRESERVATIVE; STEROID; SULFITE; VASOCONSTRICTOR AGENT;

ADD ON THERAPY; ADRENAL SUPPRESSION; ALLERGIC RHINITIS; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CARDIOTOXICITY; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CUSHINGOID SYNDROME; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD ALLERGY; HEALTH EDUCATION; HUMAN; IMMUNOTHERAPY; MEDICAL SOCIETY; MONOTHERAPY; PATIENT EDUCATION; PHARMACIST; POLLEN ALLERGY; PRICK TEST; QT PROLONGATION; QUALITY OF LIFE; SEDATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOUTH AFRICA; SYSTEMIC DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

HUMANS; INCIDENCE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SOCIETIES, MEDICAL; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 33846070515     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. South African Rhinitis Working Group. Consensus document: Allergic rhinitis in South Africa - diagnosis and management. S Afr Med J 1996; 56:1315-1328.
2. Bousquet J, Van Cauwenberge P, Khaltaer N, et al. Allergic rhinitis and its impact on asthma: A WHO-World Allergy Organization Workshop Report. J Allergy Clin Immunol 2001; 108: Suppl, S147-S152.
3. Shekelle PG, Woolf SH, Eccles M, et al. Developing guidelines. BMJ 1999; 318:593-596.
4. Bousquet J. The new ARIA guidelines: Putting science into practice. Clin Exp Allergy Rev 2002; 2: 38-43.
5. Potter PC. Evidenced based treatment of allergic rhinitis: a South African perspective. Specialist Forum 2003; 16: 28-38.
6. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21:77-83.
7. Potter PC, Thomas H, Terblanche L. Quality of life and Global score as an index of assessment of outcomes in patients on sublingual immunotherapy. Curr Allergy Clin Immunol 2006; 19:161.
8. Burns M, Moskovitz H. Effects of diphenhydramine and alcohol on skills performance. Eur J Clin Pharmacol 1980; 17: 259-266.
9. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy Asthma Immunol 1993; 71:121-126
10. Snyman JR, Potter PC, Groenewald M, Levin J. Effect of betamethazone and loratadine combination therapy on severe exacerbations of allergic rhinitis: a randomised controlled trial. Clin Drug Invest 2004; 24: 265-273.
11. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004; 5: 679-685.
12. Price D, Hernandez D, Magyar P. Clinical outcomes with Montelukast as partner agent to carticosteroid therapy (COMPACT Study): A randomised controlled trial of Montelukast plus inhaled budesomide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-216.
13. Wilson AM, O'Byrne PM, Parameswaran, K. Leukotriene receptor antagonists for allergic rhinitis: A systematic review and meta-analysis. Am J Med 2004; 116: 338-344.
14. Potter PC. Update on sublingual immunotherapy. Ann Allergy Asthma Immunol 2006; 96: Suppl 1, S22-S25.
15. Klinchi MS, Paulsen L, Carat F, Andre C, Hansen AB, Malling H. Clinical efficacy of sublingual and subcutaneous birch pollen allergen specific immunotherapy: a randomised placebo controlled double blind double dummy study. Allergy 2004; 59: 45-53.
16. Wilson DR, Torres Lima I, Durham SF. Sublingual immunotherapy for allergic rhinitis. (Cochrane Review), Cochrane Database Supt rev, 2003; 2: CD002893.
17. Andre C, Vak'riret C, Galvan S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121: 229-234.
18. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post marketing surveillance study of the safety of sublingual immunotherapy in paediatric patients. Allergy 1999; 54: 1220-1225.
19. The Medicines and Related Control Act 101 of 1965 and Act 59 of 2002 Section 22F.
20. Passalacqua G, Bousquet PJ, Carlsen K, et al. ARIA update: I-Systematic, review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117: 1054-1062.
21. Bousquet J, Van Cauwenberge P, Khaltaer N, eds. Pocket booklet: Management of Allergic Rhinitis Symptoms in the Pharmacy. ARIA in the pharmacy. Based on the allergic rhinitis and its impact on asthma workshop report in collaboration with the World Health Organization, San Antonio, 17 November 2002. www.whiar.com